{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:55:42Z","timestamp":1783540542407,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.thromres.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T20:49:01Z","timestamp":1683578941000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4198-6780","authenticated-orcid":false,"given":"Joost C.M.","family":"Meijers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-7966","authenticated-orcid":false,"given":"Kamran","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-9139","authenticated-orcid":false,"given":"Alex","family":"Zwiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-2647","authenticated-orcid":false,"given":"Stephan L.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2023.05.003_bb0005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2023.05.003_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2023.05.003_bb0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J. Thromb. Thromb."},{"key":"10.1016\/j.thromres.2023.05.003_bb0020","article-title":"Urgent reversal of vitamin K antagonists","volume":"360","author":"Hunt","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2023.05.003_bb0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ACO.0000000000000697","article-title":"Reversing anticoagulation in the hemorrhaging patient","volume":"32","author":"Treml","year":"2019","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.thromres.2023.05.003_bb0030","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2023.05.003_bb0035","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of Oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2023.05.003_bb0040","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of Dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2023.05.003_bb0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.05.003_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.thromres.2023.05.003_bb0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2023.05.003_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2012.06.055","article-title":"Cyclodextrins","volume":"453","author":"Kurkov","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.thromres.2023.05.003_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","article-title":"Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.thromres.2023.05.003_bb0070","first-page":"49","article-title":"Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent","volume":"2","author":"Welliver","year":"2009","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.thromres.2023.05.003_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.thromres.2023.05.003_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/SHK.0000000000000848","article-title":"The reversal of direct Oral anticoagulants in animal models","volume":"48","author":"Honickel","year":"2017","journal-title":"Shock"},{"key":"10.1016\/j.thromres.2023.05.003_bb0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1152\/jappl.1959.14.6.943","article-title":"Biologic assay of a thrombosis-inducing activity in human serum","volume":"14","author":"Wessler","year":"1959","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.thromres.2023.05.003_bb0090","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.21037\/cdt.2017.08.10","article-title":"Animal models of venous thrombosis","volume":"7","author":"Albadawi","year":"2017","journal-title":"Cardiovascular Diagnosis and Therapy"},{"key":"10.1016\/j.thromres.2023.05.003_bb0095","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s10311-020-01156-w","article-title":"130 years of cyclodextrin discovery for health, food, agriculture, and the industry: a review","volume":"19","author":"Morin-Crini","year":"2021","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.thromres.2023.05.003_bb0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4097\/kjae.2013.65.6.495","article-title":"Sugammadex: clinical development and practical use","volume":"65","author":"Fuchs-Buder","year":"2013","journal-title":"J. Korean J. Anesthesiol."},{"key":"10.1016\/j.thromres.2023.05.003_bb0105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:50:21Z","timestamp":1758736221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"alternative-id":["S0049384823001299"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.003","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}